Producer
AbbVie Inc
US biopharmaceutical; acquired Allergan 2020; markets Restasis (cyclosporine 0.05% ophthalmic emulsion) for dry-eye disease; historically vertically integrated cyclosporine A API supply.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input AbbVie Inc supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something AbbVie Inc makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Immunology (Humira + Skyrizi + Rinvoq)
55%Aesthetics & Neurotoxins (Botox + Juvederm)
20%Oncology & Hematology
15%Ophthalmology & Other
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
AbbVie's Botox (botulinum toxin type A, acquired via Allergan 2020) is the most striking example in modern pharmaceuticals of a single molecule serving wildly different patient populations: (1) Cosmetic — Botox Cosmetic is injected to reduce facial wrinkles; it is the #1 minimally invasive cosmetic procedure in the US; (2) Chronic migraine prevention — FDA-approved in 2010; Botox injected around the head and neck every 12 weeks prevents chronic migraine (15+ headache days/month); provides relief to 4+ million US chronic migraine patients; (3) Pediatric cerebral palsy spasticity — Botox is injected into spastic muscles in children with cerebral palsy to reduce muscle tone and improve mobility; a neurological application serving children with brain injury; (4) Overactive bladder — Botox injected into the bladder wall to reduce urgency urinary incontinence; (5) Hyperhidrosis — excessive sweating treated with Botox injections to sweat glands. The same AbbVie/Allergan manufacturing supply chain that produces Botox for cosmetic dermatology practices simultaneously supplies pediatric neurology clinics treating children with cerebral palsy and urology practices treating bladder dysfunction. A cosmetic procedure drug is also critical medical infrastructure across multiple therapeutic specialties.
AbbVie Inc. (Allergan) ↗Incident2018
Allergan (acquired by AbbVie in 2020) employed an aggressive patent strategy to extend Restasis exclusivity beyond its expected 2014 patent expiration date. In 2017, Allergan executed a highly controversial patent transaction: it assigned its Restasis patents to the Saint Regis Mohawk Tribe (a Native American sovereign nation in upstate New York) in exchange for $13.75M upfront and $15M annual royalties — with the tribe then licensing the patents back to Allergan. The purpose was to use the tribe's sovereign immunity to shield the patents from inter partes review (IPR) at the USPTO, which generic manufacturers had initiated to invalidate the patents. Federal courts ultimately ruled the strategy invalid (the Federal Circuit held tribal sovereign immunity does not extend to IPR proceedings in 2018), but the attempt itself became a landmark example of pharmaceutical companies using legal creativity to extend drug exclusivity. The same Restasis whose API supply chain is now substantially dependent on Indian and Chinese generic producers was once the center of an $800M-per-year US pharmaceutical market manipulation attempt involving a Native American tribe's sovereign immunity rights.
Reuters ↗Origin2023
AbbVie was spun off from Abbott Laboratories in 2013 — a separation of Abbott's pharmaceutical research business from its diagnostic/nutrition/device businesses. Abbott had developed Humira (adalimumab) in collaboration with BASF Pharma in the late 1990s; Humira launched in 2002 as the first fully human monoclonal antibody. AbbVie inherited Humira and built the world's most commercially successful drug on it — generating over USD 200 billion in cumulative sales from 2002 to 2022. Humira's commercial dominance was partly maintained through a pharmaceutical strategy that became regulatory shorthand for 'patent thicketing': AbbVie filed approximately 100+ patents on Humira's devices, formulations, manufacturing processes, and uses (not just the core molecule) — creating a patent thicket that delayed US biosimilar competition until 2023. The FTC issued a report in 2024 citing AbbVie's Humira as a case study for patent system abuse in pharmaceutical markets. The drug is now off patent and facing biosimilar competition; AbbVie's post-Humira strategy relies on Skyrizi and Rinvoq as the transition to the next immunology drug generation.
AbbVie Inc. ↗